Endorphin Global

Semaglutide

GLP-1 therapy trusted for significant, sustained weight reduction and improved cardiometabolic markers.

Reduced cravings and stabilized hunger
Steady, sustainable fat loss
Evidence-based safety and efficacy

New Patients Only Plans

Results

Weight Loss

Average 15% body weight loss

Reduced waist circumference

Decreased BMI

Cardiovascular

Reduced risk of major cardiovascular events

Improved blood pressure

Better cholesterol levels

Administration

Starting dosage: 0.25 mg once weekly

Maintainance dosage: 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg

Injection Site: Abdomen, thigh, or upper arm

Side Effects

Common ( >10% ):

Nausea

Diarrhea

Vomiting

Constipation

Less Common ( 5-10% ):

Headache

Fatigue

Dyspepsia

Abdominal pain

Preacaution

History of thyroid C-cell tumors

Pancreatitis

Diabetic retinopathy complications

Kidney problems

Disclaimer

The content provided is for educational and informational purposes only. It is not medical advice, nor should it be used as a substitute for professional diagnosis or treatment. Always consult a licensed physician or other qualified healthcare provider with any questions regarding your health, medical condition, or treatment options. Do not ignore or delay seeking professional medical advice because of something you have read, heard, or accessed through this platform. Any reliance on the information provided is at your own risk.